Mitosis Phase Enrichment with Identification of Mitotic Centromere-Associated Kinesin As a Therapeutic Target in Castration-Resistant Prostate Cancer
Figure 3
Overexpression of MCAK with clinical progression of prostate cancer.
MCAK-immunostained sections of castration-resistant adenocarcinoma (A), castration-resistant small cell carcinoma (B), and hormone-sensitive prostate carcinoma (C). D) Significantly increased labeling for the mitotic centromere-associated protein MCAK with progression to CRPC, indicated by asterisks.